<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584151</url>
  </required_header>
  <id_info>
    <org_study_id>VINMEC LT REC</org_study_id>
    <nct_id>NCT04584151</nct_id>
  </id_info>
  <brief_title>Perioperative Analgesia by ESP Catheter on Recipient for Liver Transplantation</brief_title>
  <acronym>ESPLIVERRec</acronym>
  <official_title>Does Bilateral Continuous Peri Operative Erector Spinae Plane (ESP) Block Improve the Enhanced Recovery Program After Liver Transplantation in Recipient Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vinmec Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vinmec Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enhanced recovery after surgery (ERAS) programs were developed by Prof Henrik Kehlet in&#xD;
      Denmark to reduce the hospitalization and improve the surgical outcomes. In these programs&#xD;
      pain relief by regional analgesia techniques are highly recommended to reduced as much as&#xD;
      possible the opioids used with their side effects. This program was created for colo-rectal&#xD;
      surgeries and extended to other surgeries. In Liver transplants different programs has been&#xD;
      described top reduce the use of peri-operative opioids but no with the ESP Animal and&#xD;
      molecular studies in chronic pain showed the activation of glial cells, Monocytes and&#xD;
      lymphocite K similar to the reaction during severe septis with immune reaction and toll like&#xD;
      receptor activation. Regional anaesthesia analgesia is blocking this activation of Tool Like&#xD;
      Receptors (TLR4) One of the discharge criteria after liver transplantation is the equilibrium&#xD;
      of plasmatic cyclosporin Our hypothesis is with regional analgesia to avoid any immune&#xD;
      disorder due to pain and reach earlier the discharge criteria than with standard analgesia&#xD;
      Improve the quality of recovery and reduce the hospitalization stay after liver&#xD;
      transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Goals:&#xD;
&#xD;
           Compare quality of analgesia and quality of recovery between bilateral ESP bilateral&#xD;
           catheters versus Opioid analgesia in adult included in an enhanced recovery program&#xD;
           after liver transplantation Show that the addition of peri-operative regional analgesia&#xD;
           improves the enhanced recovery program after open liver transplant in recipient patient&#xD;
           .&#xD;
&#xD;
        2. Methodology:&#xD;
&#xD;
           •Selection criteria: Age &gt; 18 years old Have a clinical indication for Liver&#xD;
           transplantation ( list for surgeries listed in full proposal) Agree to participate in&#xD;
           the trial&#xD;
&#xD;
           •Exclusion criteria: Use of chronic opioid Contra-indication tom perform ESP catheter&#xD;
           (Infection near puncture point, Severe thoracic scoliosis, allergy to local&#xD;
           anaesthetics) A diagnosis of a chronic pain condition Depression or other psychiatric&#xD;
           diagnosis&#xD;
&#xD;
           • Study design: Prospective Randomized Controlled Trial.&#xD;
&#xD;
           Patients who agree to join the study will be randomized into 2 groups:&#xD;
&#xD;
           Group 1 (Control group): standard of care in Liver donation : Intra operative analgesia&#xD;
           by Opioid Sufentanil and post operative analgesia by Patient Controlled analgesia (PCA)&#xD;
           opioid morphine Group 2 (treatment group): Standard peri-operative analgesia for Liver&#xD;
           donation in our hospital since we use regional anaesthesia as first line treatment for&#xD;
           peri operative analgesia Bilateral ESP catheters with continuous regional analgesia by&#xD;
           infusion of local anaesthetic (Ropivacaine)&#xD;
&#xD;
           Sample size: We expected to reduce the length of stay for liver receipt from 11 ± 2.22&#xD;
           days in ERAS group to 8 ± 2.22 days in the ESP group The sample size of 10 patients per&#xD;
           group is required to detect such changes assuming a confidence interval of 95% with a&#xD;
           power of 90% and alpha = 0.05. Considering 20% of drop-out, the total sample size is 40&#xD;
           patients (20 patients each group)&#xD;
&#xD;
        3. Project outcomes:&#xD;
&#xD;
             -  Primary outcomes Length of stay in Hospital Our estimation based on our previous&#xD;
                studies for ESP and the literature for ERAS programs in open heart surgeries&#xD;
&#xD;
             -  Secondary outcomes Time to extubation Duration of stay in ICU Time to 1st&#xD;
                mobilisation Opioid consumption in relation with VAS Rest and mobilization&#xD;
&#xD;
      Patient satisfaction:&#xD;
&#xD;
        -  Quality of recovery scoring 15 items (QOR 15)&#xD;
&#xD;
        -  Pain at 1 month rest and mobilization + Quality of Life scoring (QOL36)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled prospective trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>up to 30 day</time_frame>
    <description>Time to reach the criteria of hospital discharge after liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in Intensive care Unit (ICU)</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Time to reach the criteria of ICU discharge after liver transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery: score</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Score on 15 criteria for quality of recovery from 0= very poor to 150 = excellent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Liver Transplant Disorder</condition>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Peri operative analgesia by opioid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous regiona analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peri operative algesia by continuous bilateral ESP catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>regional analgesia</intervention_name>
    <description>Insertion of bilateral ESP catheters</description>
    <arm_group_label>Continuous regiona analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age clinical indication for liver transplantation agree to participate and signed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of chronic opioid contra indication to perform ESP cathters Diagnosis of a chronic&#xD;
             pain condition except liver disease Psychiatric or depression disorder allergy to&#xD;
             local anesthetics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mai hoang</last_name>
    <phone>+842439743556</phone>
    <phone_ext>3075</phone_ext>
    <email>v.maihn@vinmec.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>VinMec INternational hospital</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Macaire, MD</last_name>
      <phone>0966103845</phone>
      <email>ph.macaire@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VinMec INternational hopspital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Macaire, MD</last_name>
      <phone>0966103845</phone>
      <email>ph.macaire@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Viet Vu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

